Drugs
Bristol Licenses Arthritis Drug: BioBuzz
More Biotechs in the ASH spotlight
Onyx Pharmaceuticals(ONXX) brings to ASH this year its second-generation protease inhibitor carfilzomib, which the company acquired after purchasing Proteolix in October. Investors will be scrutinizing a response rate data from a phase II study of carfilzomib in relapsed or refractory multiple myeloma patients. Particularly important will be data on the benefit of carfilzomib treatment in a subset of patients progressing after prior Revlimid and Velcade treatment. Ariad Pharmaceuticals(ARIA) was upgraded Monday, in part, because of expectations for strong data at the ASH meeting from a phase I proof-of-concept study for its drug AP-24534 in chronic myeloid leukemia. The ASH focus for Cephalon(CEPH) this year will be on its cancer drug Treanda, specifically additional data from an investigator-led study testing a combination of Treanda plus Rituxan against Rituxan plus chemotherapy in patients with non-Hodgkin's lymphoma. Rituxan is a mainstay treatment for NHL marketed by Roche/Genentech. -- Reported by Adam Feuerstein in Boston.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |
Connect with TheStreet